Sometimes things just deserve to go viral, like the Backyard Squirrel Maze. They bring people together and are good for the soul. Others, like viruses that attack our bodies and cripple our economies, deserve to be pounded into submission like a second tier WWE (WWE) wrestler. 🥊

Pfizer (PFE) has helped the world put viruses on the ropes before. It’s almost exactly two years since Pfizer and BioNTech (BNTX - ADR) dropped the news of a vaccine 90% effective in preventing COVID-19. The vaccine not only helped to free us from our weird obsession with banana bread, but was a boon for Pfizer, helping the company to almost double revenue in one year. 📈

Now Pfizer is hoping it can double down to fight a new triple threat of invisible foes. A new wave of Covid, plus surges in ’flu and the respiratory virus RSV means the US could be heading for triple-demic winter smackdown. That’s the last thing overwhelmed hospitals (and parents) need. But last week Pfizer announced a new top-tier fighter - an RSV vaccine given to mothers during pregnancy that is up to 81% effective at preventing severe cases of the illness. 💉

And in an epic John Cena/Louis Pasteur tag-team, Pfizer is again teaming up with ally BioNTech. The pair are taking a shot at producing a combined Influenza and Covid-19 vaccine cocktail using messenger RNA (mRNA) technology. 🧬

Separately, BioNTech is using the same mRNA technology to develop personalised cancer vaccines. Just like you customise your coffee order, personalised cancer vaccines could be made to order and would prompt a patient’s immune system to attack their cancer cells. MRNA specialists Moderna (MRNA) are also teaming up with heavy-hitters Merck (MRK) on a similar vaccine specifically targeting melanoma. John Cena (and Louis Pasteur) would be proud. 👨🔬